Increased risk of hemorrhage in metastatic colorectal cancer patients treated with bevacizumab: An updated meta-analysis of 12 randomized controlled trials

BACKGROUND: As an important antivascular endothelial growth factor monoclonal antibody, bevacizumab has been administrated for the treatment of cancer patients. Hemorrhage, one of the common adverse events of angiogenesis inhibitors, sometimes is also fatal and life-threatening. We aimed at determin...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Xiaoqiang, Tian, Xianglong, Yu, Chenyang, Hong, Jie, Fang, Jingyuan, Chen, Haoyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2016
Materias:
4500
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5400309/
https://www.ncbi.nlm.nih.gov/pubmed/27559943
http://dx.doi.org/10.1097/MD.0000000000004232

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5400309/
https://www.ncbi.nlm.nih.gov/pubmed/27559943
http://dx.doi.org/10.1097/MD.0000000000004232

Ejemplares similares